OncoMatch/Clinical Trials/NCT04795882
A New Study Evaluating the Activity of Modular CAR T for mYeloma
Is NCT04795882 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including BCMA CAR T cells and BCMA/CD19 CAR T cells for multiple myeloma.
Treatment: BCMA CAR T cells · BCMA/CD19 CAR T cells — This is a Phase 1 rolling 6 trial design evaluating safety of a novel BCMA Chimeric Antigen Receptor (CAR) alone and of CAR T cells engineered to co-express BCMA CAR and a CD19 CAR in patients with relapsed / refractory Multiple Myeloma. The study will assess the feasibility of generating these Advanced Therapy Investigational Products (ATIMPs) and the safety of administering the CAR T cells (either BCMA alone or co-expressed with CD19) in patients with relapsed / refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)
Must have received: IMiD
≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)
Must have received: anti-CD38 antibody
≥3 prior lines of therapies (including proteasome inhibitor, IMiD, anti CD38 antibody)
Cannot have received: gene therapy
Prior treatment with investigational or approved gene therapy or cell therapy products
Cannot have received: cell therapy
Prior treatment with investigational or approved gene therapy or cell therapy products
Lab requirements
Blood counts
Absolute Neutrophil Count (ANC)≥1x10^9/L, Platelets (plt)≥50x10^9/L, Haemoglobin (Hb)≥80 /L, lymphocyte count ≥0.3x10^9/L
Kidney function
Creatinine Clearance (CrCl)≥40ml/min; Chronic renal impairment requiring dialysis [excluded]
Liver function
alanine aminotransferase or aspartate aminotransferase ≥3x upper limit normal (ULN), or total bilirubin ≥25umol/L (1.5mg/dL), except in patients with Gilbert's syndrome, or evidence of end-stage liver disease (e.g. ascites, hepatic encephalopathy)
Cardiac function
Left ventricular ejection fraction < 50% (ECHO or MUGA) [excluded]; Corrected QT interval (QTc)>470 ms on ECG [excluded]; Uncontrolled cardiac arrhythmia (patients with rate-controlled atrial fibrillation are not excluded); Oxygen saturation ≤ 90% on air [excluded]
Creatinine Clearance (CrCl)≥40ml/min, Absolute Neutrophil Count (ANC)≥1x10^9/L, Platelets (plt)≥50x10^9/L, Haemoglobin (Hb)≥80 /L, lymphocyte count ≥0.3x10^9/L; alanine aminotransferase or aspartate aminotransferase ≥3x upper limit normal (ULN), or total bilirubin ≥25umol/L (1.5mg/dL), except in patients with Gilbert's syndrome, or evidence of end-stage liver disease (e.g. ascites, hepatic encephalopathy); Left ventricular ejection fraction < 50% (ECHO or MUGA); Corrected QT interval (QTc)>470 ms on ECG; Oxygen saturation ≤ 90% on air
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify